1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc.

PARD
Poniard Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
150.00Market Cap
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
104.44
6.85
35.7
26.11
99.55
92.63
8.08
0.11
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-56.24
-142.77
-119.76
-220.88
-212.47
-66.28
-158.18
-153.25
-54.77
-43.28
-56.58
-52.41
-26.28
-11.22
Free Cash Flow per Basic Share
-49.35
-125.64
-191.64
-234.33
-144.91
-38.97
-149.71
-117.99
-52.16
-39.56
-39.07
-40.27
-20.73
-7.24
Dividend per Share
4.59
5.71
5.06
4.55
4.5
4.4
3.98
3.56
1.15
0.65
- -
- -
- -
- -
Book Value per Share
-1,544.84
-1,675.52
-1,594.22
-1,661.11
-1,858.4
-1,881.26
-1,860.26
-1,818.67
-642.58
-405.86
-416.59
-461.91
-373.86
-310.26
Tangible Book Value per Share
332.84
203.3
626.12
379.09
158.25
259.36
150.84
10.42
82.07
102.83
44.79
18.2
1.77
-1.63
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
1
Sales/Revenue/Turnover
9
1
4
3
11
11
1
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-61.54
-2,466.67
-508.45
-910.09
-205.02
-44.51
-1,919.9
-106,486.67
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
1
1
2
1
1
- -
4
1
2
1
1
1
Net Income, GAAP
-4
-12
-11
-24
-23
-5
-19
-21
-23
-33
-49
-46
-30
-16
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-48.35
-2,000
-321.27
-828.47
-208.91
-48.04
-1,908.47
-139,980
- -
- -
- -
- -
- -
- -
Working Capital
29
17
59
31
14
26
16
-2
42
84
55
27
4
-1
LT Debt
1
- -
- -
6
5
4
4
- -
10
7
17
12
2
2
Total Equity
29
18
62
42
18
29
21
3
47
89
48
24
8
3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1
1
1
Market Capitalization
21
12
7

Working Capital

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
Total Current Assets
6
4
2
Cash, Cash Equivalents & STI
5
4
2
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
1
2
3
Payables & Accruals
1
2
3
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
116.95%
261.34%
-64.25%
Free Cash Flow
29.34%
11.15%
-31.62%
Net Income, GAAP
37.87%
11.94%
-34.26%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
47.2%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
-15.08
-11.34
-11.51
- -
-52.41
2010
-11.54
-5.55
-5.39
- -
-26.28
2011
-2.44
-2.62
-2.55
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Robert F. Caspari
Full Time Employees
7
Sector
Healthcare
Industry
Biotechnology
Address
300 Elliott Avenue West Seattle WA United States of America 98119
IPO Date
Aug 11, 1988
Website
poniard.com
Similar Companies
Advagene Biopharma Co., Ltd. (6709.TWO)
Predictive Technology Group, Inc. (PRED)
Marizyme, Inc. (MRZM)
InVivo Therapeutics Holdings Corporation (NVIVQ)
Inter Pharma Public Company Limited (IP.BK)
Haleos Labs Ltd. (SMSLIFE.BO)
Business
Poniard Pharmaceuticals, Inc. was a biopharmaceutical firm dedicated to the research and commercialization of therapies for cancer. Its primary development candidate was Picoplatin, an advanced platinum-based antineoplastic agent designed to address various solid tumor types, including small cell lung, colorectal, prostate, and ovarian cancers. The company advanced Picoplatin into a pivotal Phase III SPEAR trial for second-line small cell lung cancer treatment. Additionally, Poniard conducted Phase II evaluations of Picoplatin for metastatic colorectal cancer and castration-resistant prostate cancer as a first-line therapy, along with a Phase I study exploring an oral formulation for solid tumors. Despite demonstrating promising early activity across several indications, the Phase III SPEAR study did not achieve its primary endpoint in small cell lung cancer. This outcome led the company to reassess its development strategy and explore various strategic options, including a sale. Originally known as NeoRx Corporation, the company adopted the Poniard Pharmaceuticals, Inc. name in September 2006. Poniard Pharmaceuticals, founded in 1984, was based in Seattle, Washington. In 2011, Poniard entered into a merger agreement with Allozyne, Inc., aiming to bring Allozyne public, but this transaction was ultimately terminated due to the combined entity not meeting Nasdaq listing requirements. Following the failed merger, Poniard Pharmaceuticals was delisted from Nasdaq in early 2012, with its stock subsequently moving to the OTCQB Marketplace, and the company ceased active operations as a biopharmaceutical developer.